The Janus face of dendritic cells in cancer.
On the basis of experimental models and some human data, we can assume that tumor outgrowth results from the balance between immunosurveillance (the extrinsic tumor suppressor mechanisms) and immunosubversion dictated by transformed cells and/or the corrupted surrounding microenvironment. Cancer immunosurveillance relies mainly upon conventional lymphocytes exerting either lytic or secretory functions, whereas immunosubversion results from the activity of regulatory T or suppressor myeloid cells and soluble mediators. Although specific tools to target or ablate dendritic cells (DCs) became only recently available, accumulating evidence points to the critical role of the specialized DC system in dictating most of the conventional and regulatory functions of tumor-specific T lymphocytes. Although DC can be harnessed to silence tumor development, tumors in turn can exploit DC to evade immunity. Indeed, DCs harbor defects in their differentiation and stimulatory functions in cancer-bearing hosts and can actively promote T-cell tolerance to self-tumor antigens. In this review, we will focus on the dual role of DC during tumor progression and discuss pharmacoimmunological strategies to harness DC against cancer.
Institut Gustave Roussy (IGR), Villejuif, France.
N
N
Chaput
R
R
Conforti
S
S
Viaud
A
A
Spatz
L
L
Zitvogel
D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D019610:Cytoprotection / Q000276:immunology; D003713:Dendritic Cells / Q000502:physiology* / Q000637:transplantation; D004358:Drug Therapy / Q000639:trends; D006801:Humans; D007157:Immunologic Surveillance / Q000502:physiology; D009369:Neoplasms / Q000209:etiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D019139:Tumor Escape / Q000276:immunology / Q000502:physiology